Vancouver, BC, Las Vegas, NV – April 30, 2024 (CSE: OVAT | OTCQB: OVATF) – Ovation Science Inc. (“Ovation” or the “Company”), with its proprietary topical and transdermal cannabis products powered by its patented skin delivery technology Invisicare®, today announced the official launch of its topical product line in Nevada with Planet 13 Holdings, Inc. (CSE: PLTH | OTCQX: PLNH)  (“Planet 13”). These products will be available in store, reach customers through wholesale channels and the hemp derived products will be available online, marking an exciting expansion of Planet 13’s product offerings. The cannabis derived topicals will be manufactured at the Planet 13 SuperStore in the state-of-the-art production facility where visitors can watch products being made, further enhancing the immersive customer experience that Planet 13 is renowned for. Planet 13’s 112,000 square foot SuperStore and entertainment complex is located just off The Strip in Las Vegas. Planet 13 accounts for approximately 9-percent of the cannabis retail market share for the entire state of Nevada.

“The launch of our topical products with Planet 13 in Nevada is exciting for the Company,” said Terry Howlett, President of Ovation. “Our products have always sold extremely well in Nevada; holding the position of #1 Topical for many years.”  He added, “Planet 13 has had extensive success in the past selling our topicals, but this time with the added incentive of launching the four products under their own brand. We know consumers will also be excited to see these topicals available throughout Nevada and in turn this will generate maximum revenue for Ovation and value for our shareholders.”

“We’ve experienced great success with our topical offerings both in-store and online. Introducing a MEDIZIN branded topical line perfectly aligns with our strategic goals in Nevada, allowing us to leverage our production facility to expand our brand presence and boost wholesale revenue,” explained Bob Groesbeck, Co-CEO of Planet 13. “We’re thrilled to secure the Nevada rights to Ovation Science’s patented technology and to harness the strength of our beloved MEDIZIN brand to dominate a new product category. This endeavor marks a significant stride towards optimizing our production facility, driving revenue growth, and enhancing our gross margins.”

The Planet 13 Topical Product Line Includes:

MEDIZIN REST:

3:1 Ratio – 375mg CBD & 125mg THC – A CBD-infused transdermal cream crafted to alleviate soreness and discomfort to foster relaxation for a restful night’s sleep.

MEDIZIN RECOVERY:

1:1 Ratio – 250mg CBD & 250mg THC – An ideal blend of CBD and THC to unlock the combined benefits of both cannabinoids to conjure the entourage effect

MEDIZIN RELIEF:

1:10 Ratio – 50mg CBD & 500mg THC – A THC-dominant transdermal cream designed to provide relief, complemented by CBD to balance the effects.

PLANET 13 PURE CBD:

Planet 13 PURE CBD with 400mg CBD per jar. A transdermal CBD cream designed to provide relief and promote relaxation.

Ovation leverages its expertise in the pharmaceutical industry by using its patented skin delivery technology Invisicare® in its highly effective, proprietary products. Invisicare, backed by over 20 years of research and development, enables substantially more CBD and THC and other cannabinoids to be delivered to and through the skin, which translates into better results for patients. In a recent in-house study, Ovation compared five CBD brand leaders to Ovation Science’s topical CBD cream. All competitor creams tested release less than 2% CBD compared to 40% release from Ovation Science products.

Statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

About Planet 13

Planet 13 (https://planet13.com/investors/) is a vertically integrated cannabis company, with award-winning cultivation, production and dispensary operations across its locations in California, Nevada, Illinois, and upcoming sites in Florida. Home to the nation’s largest dispensary located just off The Strip in Las Vegas, Planet 13 continues to expand its footprint. With the recent debut of its first consumption lounge in Las Vegas, DAZED!, and the opening of its first Illinois dispensary in Waukegan, bringing unparalleled cannabis experiences to the Chicago metro area. Planet 13 holds a medical marijuana treatment center license in Florida allowing for state-wide expansion throughout the Sunshine State. Planet 13’s mission is to build a recognizable global brand known for world-class dispensary operations and innovative cannabis products. Licensed cannabis activity is legal in the states Planet 13 operates in but remains illegal under U.S. federal law. Planet 13’s shares trade on the Canadian Securities Exchange (CSE) under the symbol PLTH and are quoted on the OTCQX under the symbol PLNH.

About Ovation Science Inc.

Ovation Science Inc. and its wholly-owned subsidiary; Ovation Science USA Inc., is a research and development company that develops topical and transdermal CBD/THC and other cannabinoid products which are out-licensed and also distributed under Ovation’s own brands; ARLO CBD Beauty and InVibe® MD (“wellness” line); all powered by its patented Invisicare® skin delivery technology. Invisicare enhances the delivery of ingredients to and through the skin and is protected by patents and proprietary formulations which cannot be duplicated. With over 20 years of pharmaceutical drug delivery experience, Ovation’s management and science team have created a unique pipeline of over thirty proprietary medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from royalties on licensees’ sales and the sale of Invisicare, along with revenue from its own product sales. Ovation has offices in Vancouver, Canada and Las Vegas, USA.

Stock symbols:  CSE: OVAT and OTCQB: OVATF

Websites:

CORPORATE:  www.ovationscience.com

WELLNESS: www.invibemd.com

BEAUTY: www.arlocbdbeauty.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance of sales and acceptance of its products in any of the state or country cited, continued sales in dispensaries or in retail markets or expansion to other states or countries. There are no guarantees of future performance or changes to regulations. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.’s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law.

Neither the Canadian Securities Exchange, OTC Markets nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

CORPORATE INQUIRIES:

Doreen McMorran: info@ovationscience.com  PH:  604-982-5700

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as “expects”, “will”, “anticipates”, and “estimates”; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief “snapshot” of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled “Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

FRANKFURT, Germany & LONDON, September 20, 2023–(BUSINESS WIRE)–International medical cannabis company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN, WKN: A3DG83) announces that Akanda (the “Optionee” the “Company”) and 1107385 B.C. LTD (the “Owner“) have agreed upon terms to purchase farming land and related operations and licenses.

The key deal terms are as follows:

Akanda will issue a non-refundable payment equal to One Million Eight Hundred Thousand United States Dollars (USD1,800,000) and if paid in common shares of Akanda will be based on formula to calculate the per share price as set forth in the agreement. The initial payment will be broken up into the First Option Payment, the Second Option Payment and the Third Option Payment, upon signing, 15 days after signing, 30 days after signing respectively.

This buys Akanda the right to develop the property for two years. The Company plans during this time period to develop Tetrahydrocannabinol (THC) and CBD facilities at this site. Additional payments will be made based upon milestones achieved from the development. Additional milestones include THC cultivation, sales of product, CBD cultivation, and Hemp cultivation. This is similar to a mining agreement where operators buy the right to mine a site. In this case the Company has purchased the right to develop the farming land.

Further payment milestones include:

• Upon approval or a license for THC cultivation on the property from the applicable regulatory authority, $500,000 will be paid to the Owner.
• Upon sale of THC product cultivated from the property, $500,000 will be paid
• Upon Hemp cultivation approval from the application regulatory authority, $750,000 will be paid
• Upon CBD cultivation approval from the application regulatory authority, $750,000 will be paid

About Akanda Corp.

Akanda is an international medical cannabis and wellness platform company seeking to help people lead better lives through improved access to high quality and affordable products. Akanda’s portfolio includes Holigen, a Portugal-based cultivator, manufacturer and distributor with a prized EU GMP certified indoor grow facility; CanMart, a UK-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the UK. The Company’s seed-to-patient supply chain also includes partnerships with California-based Cookies, the most globally recognized cannabis company in the world; Cansativa Group, a leading importer and distributor of medical cannabis in Europe; and Cellen Life Sciences’ Leva Clinic, one of the first fully digital pain clinics in the UK.

Cautionary Note Regarding Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Akanda’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Akanda’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking information may relate to anticipated events or results including, but not limited to business strategy, product development and sales and growth plans. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Akanda does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230920711237/en/

Contacts

Investor Contact
ir@akandacorp.com

Media Contact
Imogen Saunders
Irvine Partners
imogen@irvinepartners.co.uk

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Just as some cannabis strains have a reputation for “locking” you to your couch, there are a variety of strains that can give you subtle energy, a confidence boost, and relaxation to heighten your romantic experience and culminate in an incredibly sensual encounter.

When choosing which strain to use on date night, you may initially rely on the two overarching cannabis categories to decide how you want to feel; indica for relaxation and sativa for energy. However, the nuances of each strain and how it will affect you are also influenced by terpenes, the compounds that create those distinct strain aromas.

With these nuances in mind, we’re outlining 10 cannabis strains of both indica and sativa varieties that could be your perfect aphrodisiac for an erotic night with your special someone.

Atomic Northern Lights

This indica-dominant hybrid helps you relax and heightens arousal, making it a great choice for unwinding with your partner after a long day at work.

Blue Dream 

Potent but balanced, this strain gives a tasty blueberry buzz with all the great energy of its high sativa content. Then you’ll drop into a serious calm or even numb state, so make sure you take your hits right before the action starts.

Bubblegum Kush

This indica-dominant strain comes on slowly, but its long-lasting effects leave your senses heightened to every touch, and your mind and body relaxed.

Dark Milk Loves Chocolate

These chocolate edibles were explicitly designed for romantic arousal. They combine five herbal aphrodisiacs with sensory-heightening cannabis. Although we don’t generally recommend edibles for romance since they take longer to kick in, this is one tantalizing exception! Just make sure to enjoy your chocolates about 2 hours before you want the action to start.

Flo 

Flo is a sativa-dominant hybrid that gives you that classic hit of energy while still offering relaxation. It’s balanced and mild and lets you really get into the moment without getting lost in the high.

Granddaddy Purple

This strain is very indica-heavy, so don’t take too much. But it’s incredibly popular for leaving you feeling relaxed, creative, and euphoric. Granddaddy Purple is the king of getting into the flow and mellowing any potential inhibitions for a relaxed night with your sweetheart.

Green Crack 

Aromatic and refreshing, Green Crack gives you a burst of energy while soothing away stress and worry. This is the strain to take for your all-nighters, if you catch our drift.

Sour Dream

A hybrid of Blue Dream and Sour Diesel, this sativa-dominant hybrid builds your energy and inspires giddiness, so be prepared for a fit of giggles in bed.

Super Sour Diesel

Sativa-dominant and sensory-enhancing, Sour D is popular for good reason. You’ll have both the confident relaxation and the exciting headrush that can prepare you for romantic action.

Ultimate Trainwreck

A sativa-dominant hybrid with high THC content, Ultimate Trainwreck heightens arousal and euphoria. What more do we need to say? But really, this strain will give you an initial burst of energy and clarity, followed by a more profound relaxation. If you time it right, Ultimate Trainwreck could fit nicely with the rhythm of your evening.

Other great cannabis products for romance include a wide variety of THC and CBD-infused lubes & massage oils. Why not make it a complete cannabis-inspired night?

Before you start, ensure your romantic evening goes off without a hitch by trying a new strain to ensure it makes you feel the way you want it to. It’s also best to start with only a couple of hits the night of your rendezvous. 

Company announces products being available nationwide through Starseed Medicinal Medical Platform

Irwin Naturals Cannabis 25mg CBD Softgel

LOS ANGELES, March 24, 2023 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”), is proud to announce the release of Irwin Naturals Cannabis’ new CBD 25mg Softgels in Canada, available nationwide through the Starseed Medicinal Medical Group platform.

CBD 25mg Softgels are just the first of five CBD and THC products that Irwin Naturals Cannabis, through its licensing agreement with Entourage Health Corp., plans to launch nationwide in Canada over the next few months. The company’s product lineup will include a range of CBD and THC products designed in a variety of formulations to suit consumers’ varying needs.

“We’re thrilled to be launching our first cannabis product in Canada,” said Klee Irwin, founder of Irwin Naturals Cannabis. “With our CBD 25mg Softgels, we are bringing a high-quality cannabis-derived CBD oil product to allow consumers to incorporate premium CBD into their daily health regimens. We’re excited to be able to bring the benefits of CBD to consumers across the country.”

The full line of Irwin Naturals Cannabis products will be offered as softgels that utilize hemp seed oil and medium-chain triglyceride (MCT) oil. There will be five different formulations: THC (10 mg THC), CBD (25 mg CBD), 1:1 (10 mg CBD, 10 mg THC), 3:1 (30 mg CBD, 10 mg THC) and a 2:1 formulation that combines THC and the cannabinoid CBN (10 mg THC, 5 mg CBN).

Irwin Naturals was founded in 1994 and its best-in-class nutraceuticals have built it into a brand that is now recognized in 80 percent of American households.¹ It has operated profitably for the past 27 years,² and it is now seeking to use the equity and power of that brand in emerging markets like cannabis and psychedelic mental-health clinics.

Irwin Naturals first entered into the cannabis industry in 2018 when it began infusing hemp-based CBD into its herbal supplements available in the United States. This year, it began expanding its brand to products with THC, with the goal of becoming the first household brand to have its products available in all 38 states where cannabis is currently legal. Because cannabis is not legal at the federal level in the United States, Irwin Naturals Cannabis has gone state by state, reaching licensing agreements with cannabis manufacturers. It has already announced agreements in nine states. This agreement with Entourage in Canada means that Irwin Naturals Cannabis products will achieve not just national, but international distribution.

About Irwin Naturals

Irwin Naturals has been a household name and best-in-class herbal supplement formulator since 1994. It is now leveraging its brand to enter into both the cannabis and psychedelic industries. On a mission to heal the world with plant medicine, Irwin’s growing portfolio of products is available in more than 100,000 retail doors across North America where nearly 100 million people know the Irwin Naturals brand.³ In 2018, the Company first leveraged its brand to expand into the cannabis industry by launching hemp-based CBD products into the mass market. The Company is now leveraging its famous halo of brand trust with an objective to become one of the first household name brands to offer THC-based products and psychedelic mental health treatment. Irwin Naturals became a publicly traded company on the Canadian Securities Exchange (CSE) in August 2021. The Company’s shares began to be traded on the OTCQB Venture Market in November 2021. More information on the Company’s stock can be found via Bloomberg as well as the Wall Street Journal.

“Klee Irwin”
________________________________
Klee Irwin
Chief Executive Officer
T:310-306-3636
investors@irwinnaturals.com

IR Information

For investor-related information, please visit ir.irwinnaturals.com/, call (800) 883-4851, or email Investors@IrwinNaturals.com.

Press Contact

Irwin Naturals Investor Relations
Cassandra Bassanetti-Drumm
T: 310-306-3636
investors@irwinnaturals.com

Forward-Looking Information

This news release contains certain forward-looking statements that reflect the current views and/or expectations of management of the Company with respect to performance, business and future events. Forward-looking statements can often be identified by words such as “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, “objective,” or the negative of those words or other similar or comparable words. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. Forward-looking statements in this news release include statements related to information concerning the ability of the Company to perform the terms of the transaction referenced herein; the receipt of all necessary approvals, including regulatory approvals; expectations for other economic, market, business and competitive factors; and the Company actually entering into and doing business in the U.S. cannabis and psychedelics markets. Except for (i) the License and Supply Agreement announced herein and (ii) the other license and supply deals entered into referenced herein (with The Hive Laboratory, LLC, as described in the Company’s April 19, 2022 press release; with Assurance Laboratories as described in the Company’s May 13, 2022 press release; with BeneLeaves Ltd. as described in the Company’s May 24, 2022 press release; Larsen Group II LLC as described in the Company’s May 20, 2022 press release), the Company does not have any other active operations or agreements with respect to the entrance into the THC and/or cannabis markets. The potential entrance by the Company into these new business segments are in their preliminary stages and may be subject to approval from the board of directors of the Company as well as any regulatory approval, including that of the Canadian Securities Exchange. These statements are based on numerous assumptions that are believed by management to be reasonable in the circumstances, and are subject to a number of risks and uncertainties, including without limitation: board and regulatory approval, including the approval of the Canadian Securities Exchange; Irwin being able to acquire and/or enter into business relationships to enter into these new markets; the Company obtaining the required licenses; and changes to regulations and laws regarding cannabis or psychedelics. Further information on the regulatory environment and risks will be contained in future disclosures. Forward-looking statements are subject to a number of known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from that which are expressed or implied by such forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties, and assumptions which are difficult to predict. Accordingly, readers should not place undue reliance on forward-looking statements and information, which are qualified in their entirety by this cautionary statement. The Company does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

Neither the CSE nor its Market Regulator (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

¹ Consumer brand recognition information is based on a formal Company survey with a sample size of 500 randomly selected adults.
² Under several corporate structures, Klee Irwin has operated the Irwin brand profitably since 1994, as measured by EBITDA adjusted for extraordinary costs.
³ Consumer brand recognition information is based on a formal Company survey with a sample size of 500 randomly selected adults.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a48c9a62-49f3-44fa-8229-5c61e8bb3e2f

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Vancouver, British Columbia–(Newsfile Corp. – March 9, 2023) – Xebra Brands Ltd. (CSE: XBRA) (OTCQB: XBRAD) (FSE: 9YC0) (“Xebra”), a cannabis company, is pleased to report that the Mexican Health Regulatory Agency (the Mexican FDA equivalent) (the “COFEPRIS”) has granted to Xebra’s wholly owned Mexican subsidiary Desart MX, SA de CV (“Xebra Mexico”), an outright first-mover-advantage in Mexico, by officially issuing corporate cannabis authorizations to, among other things, import and acquire cannabis seeds, cultivate and harvest cannabis, process and produce cannabis, and sell cannabis products both domestically and through export.

Xebra announced on December 2^nd, 2021, that all five Supreme Court justices voted unanimously in favor of granting Xebra Mexico an irrevocable injunction to commercialize cannabis products. The final step required the COFEPRIS to deliver formal authorizations. Those authorizations have now been received by Xebra and include standard conditions concerning safety protocols, security measures, phyto-sanitation processes, pest management procedures, and customary inspection and reporting provisions. The authorizations are subject to Xebra satisfying the industry standard conditions. Notably, there are no restrictions on where in Mexico, Xebra can cultivate cannabis, nor on the size of the cultivation facilities, or the volume of processing and manufacturing operations. The authorizations will initially apply specifically to the commercialization of cannabis products with low levels of THC (under 1%).

“This represents an important moment for cannabis globally with the first ever grant for full cultivation, harvesting, processing and commercial activities to a corporate entity in Mexico,” said Jay Garnett, CEO of Xebra Brands. “This grant follows years of hard work and focus by a devoted team and is only the beginning of what Xebra has laid as the foundation for growth. The path is now clear for Xebra to continue forward to unlock the commercial opportunities that exists. We are excited to start the process of engaging with potential partners and stakeholders through various commercial joint-ventures/partnerships,” states Jay Garnett, CEO.

Xebra looks forward to a productive and cooperative relationship going forward with the COFEPRIS to understand their guidance and operate within the authorizations, rules, regulations, and conditions set forth for the Mexican cannabis market.

Xebra will take a methodical approach to assessing all opportunities for partnership and growth that have been presented to it since it began the process of the application for the authorization on November 29^th, 2018. We recognize the historical importance and commercial opportunity of being granted these authorizations by the Mexican Government as a first mover company.

“We look forward to delivering to our shareholders, a plan in which we recognize the full potential of these authorizations on a similar scale to those corporations that were granted licenses through Health Canada upon legalization in Canada,” said Jay Garnett, CEO.

Xebra will provide an update on its plans for the Mexican cannabis market in coming weeks.

Please contact Xebra for more information as it unfolds its story to its shareholders, the public, and the world.

Jay Garnett
CEO

For more information contact:

+1 (833)-932-7288
ir@xebrabrands.com

Certain information contained in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements, these include, without limitation, statements regarding Xebra Brands Ltd.’s expectations in respect of its ability to successfully execute its business plan or business model; its ability to enter into and execute partnerships or joint venture opportunities on acceptable terms; its ability to provide economic, environmental, social, or any benefits of any type in the communities it operates in or may operate it in the future; its ability to be a first mover in a country, or to obtain or retain government licenses, permits or authorizations in general, or specifically in Mexico, Canada, or elsewhere, including cannabis authorizations from the Mexican Health Regulatory Agency (COFEPRIS); its ability to satisfy the conditions of authorizations granted by COFEPRIS; its ability to successfully apply for, obtain and retain trademarks and other intellectual property in any jurisdiction; its ability to be cost competitive; its ability to commercialize, cultivate, grow, or process hemp or cannabis in Mexico, Canada, or elsewhere and related plans and timing; its ability to manufacture, commercialize or sell cannabis-infused beverages, wellness products, or other products in Mexico, Canada, or elsewhere, and its related plans and claims, including market interest and availability; its ability to create wellness products that have a therapeutic effect or benefit; plans for future growth and the direction of the business; plans to increase product volumes, the capacity of existing facilities, supplies from third party growers and contractors; expected growth of the cannabis industry generally; management’s expectations, beliefs and assumptions in general, including manufacturing costs, production activity and market potential in Mexico or any jurisdiction; events or developments that Xebra expects to take place in the future; general economic conditions; and other risk factors described in the MD&A of the Company for the period ended November 30, 2022. All statements, other than statements of historical facts, are forward-looking information and statements. The words “aim”, “believe”, “expect”, “anticipate”, “contemplate”, “target”, “intends”, “continue”, “plans”, “budget”, “estimate”, “may”, “will”, and similar expressions identify forward-looking information and statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Xebra as of the dates of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements. Such factors include, but are not limited to, the inability of Xebra to retain the authorizations granted by COFEPRIS, the inability to generate sufficient revenues or to raise sufficient funds to carry out its business plan; changes in government legislation, taxation, controls, regulations and political or economic developments in various countries; risks associated with agriculture and cultivation activities generally, including inclement weather, access to supply of seeds, poor crop yields, and spoilage; compliance with import and export laws of various countries; significant fluctuations in cannabis prices and transportation costs; the risk of obtaining necessary licenses and permits; inability to identify, negotiate and complete potential acquisitions, dispositions or joint ventures for any reason; the ability to retain key employees; dependence on third parties for services and supplies; non-performance by contractual counter-parties; general economic conditions; the continued growth in global demand for cannabis products and the continued increase in jurisdictions legalizing cannabis; and the timely receipt of regulatory approvals for license applications on terms satisfactory to Xebra. In addition, there is no assurance Xebra will: be a low-cost producer or exporter; obtain a dominant market position in any jurisdiction; have products that will be unique. The foregoing list is not exhaustive and Xebra undertakes no obligation to update or revise any of the foregoing except as required by law. Many of these uncertainties and contingencies could affect Xebra’s actual performance and cause its actual performance to differ materially from what has been expressed or implied in any forward-looking statements made by, or on behalf of, Xebra. Readers are cautioned that forward-looking statements are not guarantees of future performance and readers should not place undue reliance on such forward-looking statements. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those set out in such statements.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

While large amounts of flower might require high-tolerance users to catch a buzz, it’s easy for anyone to overindulge in edibles or extracts. Below, we’ve created the ultimate guide to finding your ideal Cannabis high. Regardless of your THC tolerance level or preferred ingestion method, you can dial in your experience with these helpful tips.

Tips for Flower Users

Although THC content in flower has grown, there are ways to pace yourself and specific strains to pick to achieve the desired feelings. Small pipes like spoons and chillums are the best way to start smoking flower. Hits are more manageable for beginners, and they won’t be as concentrated as bong or bubbler tokes.

Strains will also play a large role in having mind and body effects. Newcomers should gravitate towards lower THC content strains like Blue Dream or Jack Herer, with THC percentages typically in the teens. If your tolerance is low, stick with pipes and take one or two hits every 10 to 15 minutes – this will allow plenty of time to feel the effects and moderate the experience.

Avid smokers pay close attention to THC content, and top-shelf options are now pushing 30%. Look for classics like Kosher Kush and GSC when in the market for potent plant material, and grab the bong for instant intoxication.

Sativa-dominant strains like Durban Poison will sub-in well for your morning cup of coffee, providing an uplifting, energetic high. Indica-dominant varieties are best suited for evening use. Kosher Kush, mentioned above, and Death Star are famous indicas that provide heavy sedation effects and relax body highs.

Finding the Perfect Edible High

The edible market is growing faster than any other industry segment, but proper consumption of these products remains extremely misunderstood by most of the public.

When Cannabis is consumed by smoking or vaping, the cannabinoids act directly with receptors in your brain to create instantaneous results. Edibles must be digested and processed by the liver, taking much longer to kick in and often lasting longer than other ingestion methods.

Newcomers to THC and edibles will want to take a cautious approach during the first couple of attempts. Start with a small dose, typically under 5mg, and wait a few hours before ingesting more. Eating fatty foods about an hour before can help speed up the digestive process and will provide cannabinoids more surfaces on which to bond.

Most pre-made edibles contain 10mg of THC per item, but stronger options exist for higher-tolerance users. It can often take 100mg, or more for heavy users to get their desired high, but lower dosing and adding on are still recommended in these cases. Taking edibles on an empty stomach will significantly delay results, so plan consumption around planned meals.

If common edibles aren’t enough, consider extract capsules for the market’s most potent and discrete option. These capsules are similar to gelcap pills and deliver enormous amounts of THC in a small package.

Tips on Coming Down from a Cannabis High

Almost every consumer of marijuana has a story of the time they used too much. Luckily, these stories typically end with long naps, and it’s important to remember that although you feel way too high, you’re not in any real danger.

There are also quick and easy ways to mellow out the experience if you’ve gone too far. CBD tinctures and vape products have essentially become the antidote to getting too high. With a couple of drops under your tongue or a quick hit, CBD will bond to your brain’s cannabinoid receptors and limit their interaction with the THC in your system. These products’ effects aren’t immediate, but many users feel better after just a few minutes.

Other ways to come down are a bit more traditional and are most effective when you’ve smoked or vaped THC. Eating a large meal will often dull the effects of THC and help users feel more like themselves. Taking a shower or swimming is popular with avid smokers. The water can intensify effects at times, but most users feel back to normal upon exit. Physical activity also takes your mind off the impact, and working up a sweat is almost guaranteed to bring you down.

With so many products to choose from, some experimentation and trial and error will be required. Thoroughly research strains and their effects before buying and keep doses low and slow when starting. With some practice, you’ll find the perfect high every time you toke.

Vancouver, British Columbia–(Newsfile Corp. – January 31, 2023) – Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf“, “OILS“, or the “Company“), a federally regulated manufacturer and distributor of cannabis extracts, has released its audited annual financial statements for the fiscal year ended September 30, 2022. Nextleaf is pleased to provide a summary of selected financial highlights and milestones achieved:

• Total revenue of $5,351,509, an increase over 52% from the year prior.
• Cost of sales of $3,748,621, decrease of approximately 12% from the year prior. A significant portion of cost of sales is related to excess capacity, as such, as revenue scales with increased distribution, gross profit is expected to increase exponentially.
• Gross profit of $661,238
• Cash used in operations of $802,192
• SG&A, R&D, and total operating expenses decreased year over year
• Established distribution in four provinces through government distributors and authorized retailers, and nationally through medical sales partners.
• Top 5 in CBD oil sales and Top 10 in vapes in B.C.
• Completed a public offering for gross proceeds of $3,168,842 under a prospectus supplement dated December 15, 2021, issuing 15,844,208 units at $0.20 per unit.

“Nextleaf established itself as one of the top producers of cannabis vapes and oils with the success of Glacial Gold branded products. During 2022, our business graduated from ingredient supplier into the manufacturing and distribution of branded consumer products,” said Nextleaf CEO Paul Pedersen. “Nexteaf has a clear path to profitability with its right-sized operating overhead and steadily growing revenue base.”

Cannot view this video? Visit:
https://www.youtube.com/watch?v=-MAZKpolpok

Key Milestones During the Year

Nextleaf remained a top-10 supplier of cannabis vapes and oils in British Columbia.

Nextleaf began selling Glacial Gold THC and CBD products in Ontario through the Ontario Cannabis Store (“OCS”) in May 2022, and received a number of new product listings, including for its High Plains vapes, subsequent to year end.

Nextleaf began selling Glacial Gold THC and CBD products in Nova Scotia through the Nova Scotia Liquor Corporation (“NSLC”) in February 2022.

Nextleaf began selling Glacial Gold THC and CBD products in Saskatchewan through National Cannabis Distribution.

Nextleaf began selling its Glacial Gold THC and CBD products to medical patients nationally through Quebec-based medical cannabis sales platform Mendo Medical (www.Mendocannabis.ca), and through Hybrid Pharm Inc., Canada’s first brick-and-mortar pharmacy distributing medical cannabis.

Nextleaf released the most potent ingestible CBD product in the Canadian market, with Glacial Gold Distilled CBD 200 Oil – one of B.C.’s top selling CBD products.

Figure 1 – Nextleaf manufacturing THC vapes

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/5347/153017_f1eaf91d443a3a30_001full.jpg

Innovation and Intellectual Property

Nextleaf is a global leader in cannabinoid innovation and intellectual property. The Company has been issued 19 U.S. patents, and 100 patents globally, on cannabinoid processing including extraction, distillation, and acetylation.

The Company validated its technology to produce THC-free Broad Spectrum CBD distillate from industrial hemp feedstock. Nextleaf launched its first THC-Free CBD product subsequent to year end.

Nextleaf launched its first cannabinol (“CBN”) product for sleep, with Glacial Gold After Hours CBN:THC Drops. The Company plans to expand its product offerings in the sleep category in 2023. According to Health Canada’s recent cannabis survey, sleep remains the number one reason Canadians choose cannabis as a medicine.

Nextleaf became the first in Canada to produce D9-tetrahydrocannabinol acetate (D9-THC-OAc, delta-9-THC-OAc, THC-OAc), colloquially referred to as THC-O (“THC-O”). Federal Regulators confirmed the Company’s understanding that THC-O is not subject to excise tax as it does not meet the definition of “Total THC” as defined under the Excise Act, which is aligned with the definition of the same in the Cannabis Act. With many delta-9-THC extracts subject to excise tax over 40% of the duty paid landed cost from government distributors, the Company is developing its novel THC-O cannabinoid ingredient as a tax-free alternative to delta-9-THC products, and sees significant opportunity for market disruption.

Key Milestones Subsequent to Fiscal Year 2022

Nextleaf expanded its product mix into cannabis softgel capsules, with the launch of Glacial Gold THC 10mg Softgels in a 50-pack large format, and 10-pack trial size to address the market for edible cannabis products with more THC per package versus traditional edibles.

The Company entered the Newfoundland and Labrador market through a strategic partnership with Atlantic Cultivation Inc. (“Atlantic”), the number one distributor in the province by sales revenue and market share.

Nextleaf launched its new High Plains brand with a lineup of four high flavour vape SKUs in British Columbia.

Nextleaf partnered with NOYA Cannabis for the Canadian Launch of Cookies “C” branded vapes, with four unique flavours formulated with high-potency distillate produced by Nextleaf’s patented ingredient processing technology.

Nextleaf completed its first international shipment of cannabis vape products. Cannabinoid vapes custom manufactured by Nextleaf under private label will be sold by pharmacies outside Canada where medical cannabis is legal.

The Company amended the terms of the senior secured note (the “Note”) issued to an institutional investor (the “Investor”) on March 31, 2021, extending the maturity date of the Note to June 1, 2023.

Financial Statements

The consolidated audited financial statements of the Company for the year ended September 30, 2022 and accompanying MD&A have been filed with the securities regulators and are available on SEDAR at www.sedar.com under the Company’s issuer profile.

About Nextleaf Solutions Ltd.

Nextleaf® is a federally regulated manufacturer and distributor of cannabis vapes and oils under its award-winning prohibition-era brand, Glacial Gold. The Company sells its branded products through government distributors and authorized retailers in 4 provinces in Canada. Nextleaf is a low-cost producer of cannabis oils, and supplier of THC and CBD to qualified wholesale partners across Canada and internationally. Nextleaf’s patented ingredient processing technology transforms cannabis and hemp biomass into high-purity distillate at an industrial scale. The Company has been issued 19 U.S. patents, and 100 patents globally, on cannabinoid processing including extraction, distillation, and acetylation.

Nextleaf trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

For more information visit www.nextleafsolutions.com and www.Glacial.Gold

Follow Glacial Gold on social platforms: Instagram, Twitter, and Facebook.

[email protected] 604-283-2301 (Ext 205)

On behalf of the Board of Directors of the Company,
Paul Pedersen, CEO

Certain statements contained in this press release constitute “forward-looking statements” within the meaning of applicable securities laws. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding the Company’s financial results and those regarding the Company’s strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company’s MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The Canadian Securities Exchange has not reviewed or approved the contents of this press release.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as “expects”, “will”, “anticipates”, and “estimates”; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief “snapshot” of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled “Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

Smaller bottle allows for consumers flexibility at a more affordable price

SAN DIEGO, Jan. 19, 2023 /PRNewswire/ — CV Sciences, Inc. (OTCQB: CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced the launch of their popular +PlusCBD Reserve Collection Softgels in a 30-count bottle. This new offering will be available on +PlusCBD’s’ website on Thursday, Jan. 19.

+PlusCBD Reserve Collection Softgels initially launched in August 2022 as the newest edition to CV Sciences’ popular Reserve Collection, available in 60-count bottles. Reserve Softgels elicit feelings of relief and calm for consumers that require intense support. Featuring a 10:1 ratio of CBD to THC (12.5mg CBD to 1.25mg THC), Reserve Softgels are crafted with a full spectrum of cannabinoids to meet consumers’ need states with a manageable microdose. Now offering a 30-count bottle in addition to the 60-count bottle, Reserve Softgels’ size options allow consumers to better personalize their intake routines at a lower price point of $37.99 USD.

“Consumers have quickly adopted Reserve Softgels into their lifestyles, appreciating the product’s easy-to-take and familiar format as well as its life-enhancing effects,” said Joseph Dowling, CEO of CV Sciences. “Now available in a smaller 30-count bottle, Reserve Softgels are more accessible to a wider range of budgets at an affordable price. We strongly believe that this new addition will encourage more consumers, from the experts to the canna-curious, to leverage cannabis to reduce their depression, stress and anxiety.”

The +PlusCBD Reserve Collection features a variety of product form factors, including gummies and oils in different flavors and potency. Consumers find calm, comfort and relief in the +PlusCBD Reserve Collection.

For more information, visit https://www.pluscbdoil.com/ or email [email protected].

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB: CVSI) is a consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, which are sold through a range of sales channels from B2B to B2C.  The Company’s +PlusCBD branded products are sold at select retail locations throughout the U.S. and are one of the top-selling brands of hemp extracts in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry.  CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications.  With a commitment to science, +PlusCBD product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California.  Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

Wholesale Contact
[email protected]

Media Contact
MATTIO Communications
Mark Sinclair
[email protected]

Investor Relations Contact
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.